Results 41 to 50 of about 14,439 (224)
Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption
(1) Background: A biosimilar is a biologic medical product that has been approved by the United States Food and Federal Drug Administration (FDA) and is an almost identical copy of an original biologic product yet manufactured by a different company ...
John Hair +2 more
doaj +1 more source
Tendering and biosimilars: what role for value-added services?
Background: Access to biologic medicines (including biosimilars) across Europe is largely governed by a process of tendering conducted by health authorities. Over-reliance on treatment costs in awarding tenders has the potential to hinder competition and
Steven Simoens, Raymond Cheung
doaj +1 more source
Can local policies on biosimilars optimize the use of freed resources – experiences from Italy [PDF]
There is an increasing need to prescribe biosimilars to fund new medicines and increasing medicine volumes.
Allocati, Eleonora +3 more
core +2 more sources
Highly effective treatment options for rheumatoid arthritis afforded by the availability of biosimilars [PDF]
Biosimilars are biologic products that provide equal mechanisms and efficacy to that of their original biologic references. This paper aims to provide a comprehensive overview of the numerous ways biosimilars are improving care for individuals living ...
Leticia A. Shea, Jamshaid S. Ahmed
doaj +1 more source
Biosimilar: what it is not [PDF]
A biosimilar is a high quality biological medicine shown to be in essence the same as an original product. The European Medicines Agency (EMA) paved the way in the regulatory arena by creating a safeguarding framework for the development of biosimilars.
openaire +2 more sources
The aim of this study is to evaluate the effect of the introduction of biosimilars in Bulgaria on the prices and utilization of biologic disease modifying antirheumatic drugs (bDMARD).
Konstantin Tachkov +3 more
doaj +1 more source
AN OVERVIEW OF BIOSIMILARS [PDF]
Biosimilars are surmounting pharmaceutical market from last three decades and sale increasing progressively. Advances in the biotechnologylead to development and discovery of new biological products to treat various life-threatening diseases. Biosimilars
Prithvi, Shruthi D +2 more
core +1 more source
Safety of switching between rituximab biosimilars in onco-hematology
Comparable clinical efficacy and safety of the reference rituximab (MABTHERA) and its biosimilars has been established in randomized trials. However, safety concerns are often raised when switching from reference to biosimilar products and between ...
Silvana A. M. Urru +4 more
doaj +1 more source
Switching Among Biosimilars: A Review of Clinical Evidence
Biological medicines have improved patients’ outcomes, but their high costs may limit access. Biosimilars, alternatives that have demonstrated high similarity in terms of quality, safety, and efficacy to an already licensed originator biological product,
Eleonora Allocati +6 more
doaj +1 more source
Biosimilar therapeutic proteins in oncology offer the potential to decrease costs while providing safety and efficacy profiles consistent with their respective reference or originator products. Biosimilars have a number of important differences from generic small-molecule drugs, including manufacturing processes that are unique from their reference ...
openaire +2 more sources

